Hi all,
Starting a new thread for people to post and discuss analyst reports about the latest AHZ annual report (as the other one has descended into the usual chaos of mindless insults).
Firstly, does anyone have access to this? Guessing they classed the result as a miss, but perhaps not given analyst expectations did not appear sky high prior to the results
https://www.fnarena.com/index.php/2017/09/01/fnarena-reporting-season-monitor-34/
Motley fool continues to revel in our misfortune (annoying that they've been proven right... thus far!
)
https://www.**promotion blocked**.au/2017/08/31/admedus-ltd-delivers-another-big-loss/
Morgans has reduced its target from 23 to 22 cents (sorry no link as I got emailed the article text). Should be able to find it somewhere, but See below if not.
Anyone else seen anything interesting?
Text from article on Morgans
"FY17 results were behind Morgans forecasts. The main achievements were the US regulatory clearance for three regenerative medicine products.
The broker increases its net loss forecast -$7.1m in FY18 to reflect a lower contribution from the R&D tax incentive. Management has guided to break even in the fourth quarter of 2018, a delay versus previous announcements.
TD
Reduce retained. Target lowered to $0.22 from $0.23.
Sector: Health Care Equipment & Services.
Target price is $0.22.Current Price is $0.25. Difference: ($0.03) - (brackets indicate current price is over target). If AHZ meets the Morgans target it will return approximately -14% (excluding dividends, fees and charges - negative figures indicate an expected loss)." Source FN Arena
(20min delay)